Safety, tolerability, pharmacokinetics, and antiviral activity of the novel core protein allosteric modulator ZM-H1505R (Canocapavir) in chronic hepatitis B patients: a randomized multiple-dose escalation trial

Abstract Background Hepatitis B virus (HBV) core protein-targeting antivirals (CpTAs) are promising therapeutic agents for treating chronic hepatitis B (CHB). In this study, the antiviral activity, pharmacokinetics (PK), and tolerability of ZM-H1505R (Canocapavir), a chemically unique HBV CpTA, were...

Descripció completa

Dades bibliogràfiques

Autors principals:	Haiyan Jia, Jiajia Mai, Min Wu, Hong Chen, Xiaojiao Li, Cuiyun Li, Jingrui Liu, Chengjiao Liu, Yue Hu, Xiaoxue Zhu, Xiuhong Jiang, Bo Hua, Tian Xia, Gang Liu, Aiyun Deng, Bo Liang, Ruoling Guo, Hui Lu, Zhe Wang, Huanming Chen, Zhijun Zhang, Hong Zhang, Junqi Niu, Yanhua Ding
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2023-03-01
Col·lecció:	BMC Medicine
Matèries:	Antiviral therapy Clinical trial Hepatitis B Pharmacokinetics
Accés en línia:	https://doi.org/10.1186/s12916-023-02814-w
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!